Phimetra vs ArteraAI
A side-by-side comparison built from both listings. Blank cells mean the company has not given that detail; we never guess.
Phimetra compared with ArteraAI
| Detail | 
Phimetra | 
ArteraAI |
|---|
| What it does | AI-assisted facial analysis and aesthetic simulation for pre-consultation support
| Personalized precision medicine powered by AI for cancer therapy
|
|---|
| Stage | Startup
| Not given
|
|---|
| Founded | 2024
| Not given
|
|---|
| Based in | FR
| US
|
|---|
| Pricing model | Freemium
| Contact for pricing
|
|---|
| Pricing | Discovery: €29/month (50 consultations, 3-day free trial). Practice: €149/month (200 consultations, 14-day free trial). Clinic: Custom pricing on quote (multi-practitioner, unlimited volume).
| Not given
|
|---|
| Key features | - Facial biometric analysis with seven computed metrics
- AI-generated before/after simulations
- Ricketts cephalometric analysis in 15 seconds
- Zone-by-zone treatment visualization
- Covers 14+ injection zones
- Pre-consultation link sharing
- Website widget integration
- GDPR Article 9 compliance with explicit consent
- EU data hosting and encryption
| - Analyzes digital pathology with no additional tissue staining required
- Rapid results within 1-2 days after specimen receipt
- Validated across diverse populations including African American and non-African American men
- FDA De Novo authorization for prostate cancer risk stratification
- Insurance coverage for Medicare and many commercial plans
- Provides 5 and 10-year distant metastasis risk for breast cancer
- Identifies breast cancer patients who benefit from chemotherapy
- Included in NCCN Clinical Practice Guidelines for Prostate Cancer
|
|---|
| What makes it different | - Measurement-based, not subjective judgment
- Respects bone structure without deformation
- Single photo, no hardware needed
- Lightweight European alternative to legacy solutions
- Results in seconds with no AI training on user photos
| - No additional tissue preparation needed, uses existing H&E slides
- Validated across multiple large randomized phase III clinical trials
- FDA De Novo clearance as Software as a Medical Device
- Financial assistance program to make tests affordable regardless of income
|
|---|
| Community votes | 0 | 0 |
|---|
| DR (Domain Rating by Ahrefs) | 2 ● no change since last check | 57 ● no change since last check |
|---|
| Trust Flow (Majestic) | 10 | 15 |
|---|
| Citation Flow (Majestic) | 12 | 27 |
|---|
| Referring domains (Majestic) | 45 | 285 |
|---|
5 details filled in for both companies.
More alternatives to Phimetra More alternatives to ArteraAI